IL-15 treatment with or without vaccine for prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a drug called IL-15 superagonist (with or without a vaccine) for men whose prostate cancer has come back (shown by rising PSA) after they already had targeted radiation therapy. The goal is to see if this treatment can lower or control PSA levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer that has returned after initial treatment, shown by a rising PSA level.
- You had a type of targeted radiation therapy (SBRT) for spots found on a PSMA scan, and your PSA went up at least 25% after that radiation.
- You are at least 18 years old and in good overall health (able to do daily activities).
- Your kidney and liver function tests are within acceptable limits.
- You do not have active infections like HIV or hepatitis, or a serious autoimmune disease.
- You have not had other cancer treatments (including steroids or hormone pills) in the last month, except as allowed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new vaccine (TriAdeno) combined with an immune-boosting drug to help your body fight early-stage prostate cancer while you're on active surveillance—a watchful waiting approach. The vaccine may help prevent cancer growth without surgery or radiation.
This trial tests a combination of a DNA vaccine (pTVG-HP) and an immunotherapy drug (nivolumab) along with targeted radiation or ablation of remaining cancer spots. It is for men whose prostate cancer has come back after surgery but hasn't spread widely.
This trial tests an experimental vaccine (2141-V11) combined with standard hormone therapy and an anti-androgen drug before prostate removal surgery. It aims to see if the combination can help the immune system fight the cancer more effectively.
This trial tests a new combination of two treatments for prostate cancer that has spread and stopped responding to hormone therapy. The goal is to see if combining an immune-boosting drug with a vaccine can help the body fight the cancer more effectively.
This early-phase trial tests pembrolizumab (an immune therapy) plus an androgen-receptor–blocking prostate cancer drug, and possibly a targeted radiation treatment. It’s for men with prostate cancer that has spread and keeps worsening despite standard hormone therapy, aiming to shrink tumors and improve control of the disease.
This trial tests a new radiation approach for prostate cancer that has not spread. It combines different types of radiation with or without hormone therapy to see if this approach works better with fewer side effects.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.